Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MIMEDX GROUP, INC.

(MDXG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MIMEDX to Present at the Piper Sandler 33rd Annual Healthcare Conference

11/22/2021 | 08:01am EST

MARIETTA, Ga., Nov. 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, and Rohit Kashyap, Ph.D., Chief Commercial Officer, will present at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29 to December 2, 2021.

Management’s presentation will be available to view on-demand beginning Monday, November 22 at 10:00 AM ET. The webcast will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com. A replay will be available on the Company’s website following the event.

Institutional investors interested in meeting with management may contact their Piper Sandler representative.

About MIMEDX
MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.MIMEDX.com.

Contacts:
Investors
Jack Howarth
404-360-5681
jhowarth@mimedx.com

Corporate Communications
Hilary Dixon
404-323-4779
hdixon@mimedx.com


All news about MIMEDX GROUP, INC.
01/10MIMEDX GROUP, INC. : Results of Operations and Financial Condition, Regulation FD Disclosu..
AQ
01/10MIMEDX Outlines Key Strategic Milestones for 2022
AQ
01/10MiMedx Group, Inc. Provides Revenue Guidance for the Financial Year 2022
CI
01/04MIMEDX to Participate at the H.C. Wainwright BioConnect Virtual Conference
AQ
2021MIMEDX to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021MIMEDX GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
2021MiMedx Lifts Adjusted Net Sales Outlook for FY21
MT
2021MIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day
AQ
2021Mimedx Group, Inc. to Provide New Details About Near- and Long-Term Growth Opportunitie..
CI
2021MIMEDX Announces Speakers for December 7 Investor Day
AQ
More news
Analyst Recommendations on MIMEDX GROUP, INC.
More recommendations
Financials (USD)
Sales 2021 255 M - -
Net income 2021 -19,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -26,4x
Yield 2021 -
Capitalization 527 M 527 M -
Capi. / Sales 2021 2,07x
Capi. / Sales 2022 1,90x
Nbr of Employees 735
Free-Float 96,6%
Chart MIMEDX GROUP, INC.
Duration : Period :
MiMedx Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIMEDX GROUP, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 4,75 $
Average target price 14,50 $
Spread / Average Target 205%
EPS Revisions
Managers and Directors
Timothy R. Wright Chief Executive Officer & Director
Peter M. Carlson Chief Financial Officer
M. Kathleen Behrens Wilsey Chairman
David H. Mason Chief Medical Officer
Robert Benjamin Stein Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
MIMEDX GROUP, INC.-21.36%527
GILEAD SCIENCES, INC.-3.00%88 346
MODERNA, INC.-26.53%75 661
REGENERON PHARMACEUTICALS-3.21%63 906
VERTEX PHARMACEUTICALS5.22%58 750
WUXI APPTEC CO., LTD.-0.66%54 178